Aliskiren therapy in hypertension and cardiovascular disease: a systematic review and a meta-analysis.
In conclusion, this meta-analysis demonstrated that aliskiren in combination therapy with ACEs/ARBs could control BP effectively, but is associated with increasing risks of hyperkalaemia and kidney injury, and have no benefit in preventing of major cardiovascular events.
PMID: 29179525 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Heart | Hypertension | Study | Tekturna | Urology & Nephrology